AMACR anticorps

N° du produit ABIN968957

L’anticorps Souris Monoclonal anti-AMACR a été validé pour WB, IHC, ELISA et ICC. Il convient pour détecter AMACR dans des échantillons de Humain et Souris. Il y a 2+ publications disponibles.

Aperçu rapide pour AMACR anticorps (ABIN968957)

Antigène: AMACR (alpha-Methylacyl-CoA Racemase (AMACR))

Reactivité: Humain, Souris

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp AMACR est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunocytochemistry (ICC)

Clone: 2A10F3

Détail du produit anti-AMACR anticorps

Fonction: AMACR Antibody

Purification: Ascitic fluid

Immunogène: Purified recombinant fragment of human AMACR expressed in E. Coli.

Isotype: IgG2b

Information d'application

Indications d'application:

ELISA: 1/10000

ICC: 1/200 - 1/1000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Références pour anticorps anti-AMACR (ABIN968957)

Chen, Watson, Marengo, Decker, Coleman, Nelson, Sikes: "Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo." dans: Cancer letters, Vol. 244, Issue 2, pp. 274-88, (2006) (PubMed).

Epstein, Herawi: "Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care." dans: The Journal of urology, Vol. 175, Issue 3 Pt 1, pp. 820-34, (2006) (PubMed).

Détails sur AMACR

Antigène: AMACR (alpha-Methylacyl-CoA Racemase (AMACR))

Autre désignation: AMACR

Sujet: AMACR (alpha-methylacyl-CoA racemase) has been recently described as prostate cancer-specific gene that encodes a protein involved in the beta-oxidation of branched chain fatty acids. Expression of AMACR protein is found in prostatic adenocarcinoma but not in benign prostatic tissue. It stains premalignant lesions of prostate: high-grade prostatic intraepithelial neoplasia (PIN) and atypical adenomatous hyperplasia. AMACR can be used as a positive marker for PIN. Defects in AMACR are the cause of congenital bile acid synthesis defect type 4 (CBAS4), also known as cholestasis, intrahepatic, with defective conversion of trihydroxycoprostanic acid to cholic acid or trihydroxycoprostanic acid in bile. Clinical features include neonatal jaundice, intrahepatic cholestasis, bile duct deficiency and absence of cholic acid from bile.

Poids moléculaire: 42 kDa

UniProt: Q9UHK6

Pathways: Monocarboxylic Acid Catabolic Process